Phaseline

Companies › Nuvig Therapeutics

Nuvig Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Hematology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NVG-2089
FcγRIIB agonist (IVIg mimetic)
FCGR2BPhase 2Chronic Inflammatory Demyelinating Polyneuropathy; Immune Thrombocytopenia (ITP)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07027111NVG-2089Phase 2Chronic Inflammatory Demyelinating PolyneuropathyNeurologyOct 2026
NCT07095127NVG-2089Phase 2Immune Thrombocytopenia (ITP)HematologyJun 2027

Targets

FCGR2B (1)

Companies with the same targets

argenx Zenas BioPharma (USA) BioInvent International

Companies built like this

Halia Therapeutics Biossil Sundance Biosciences Teikoku Pharma USA Gateway Institute for Brain Research

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.